We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
-4.59%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$17B
AUM Growth
-$724M
(-4.1%)
Cap. Flow
+$236M
Cap. Flow
% of AUM
1.39%
Top 10 Holdings %
Top 10 Hldgs %
34.54%
Holding
1,117
New
28
Increased
595
Reduced
447
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$226M |
| 2 |
iShares China Large-Cap ETF
FXI
|
+$86.1M |
| 3 |
Tesla
TSLA
|
+$57.7M |
| 4 |
Advanced Micro Devices
AMD
|
+$47.5M |
| 5 |
Rambus
RMBS
|
+$33.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$109M |
| 2 |
Broadcom
AVGO
|
+$52.1M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$44.7M |
| 4 |
Intel
INTC
|
+$34.2M |
| 5 |
ON Semiconductor
ON
|
+$29.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 42.96% |
| 2 | Financials | 10.65% |
| 3 | Healthcare | 7.83% |
| 4 | Consumer Discretionary | 4.77% |
| 5 | Energy | 4.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
United Therapeutics
UTHR
$25.8B
| $8.93M | 0.05% |
39,524
+3,210
| +9% | +$739K |
|
252
Biohaven
BHVN
$2.03B
| $8.92M | 0.05% |
342,861
+153,271
| +81% | +$3.19M |
|
|
HZNP
253
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $8.92M | 0.05% |
77,078
-6,707
| -8% | -$721K |
|
254
Cigna
CI
$73.7B
| $8.84M | 0.05% |
30,887
+2,275
| +8% | +$649K |
|
255
Halozyme
HALO
$9.79B
| $8.83M | 0.05% |
231,192
-13,353
| -5% | -$547K |
|
256
Exelixis
EXEL
$13.3B
| $8.8M | 0.05% |
402,658
-30,059
| -7% | -$629K |
|
257
TJX Companies
TJX
$174B
| $8.79M | 0.05% |
98,887
+3,428
| +4% | +$302K |
|
258
BioMarin Pharmaceuticals
BMRN
$11.6B
| $8.74M | 0.05% |
98,725
+7,851
| +9% | +$699K |
|
259
Zoetis
ZTS
$32.4B
| $8.7M | 0.05% |
50,009
+3,279
| +7% | +$595K |
|
260
Alkermes
ALKS
$8.22B
| $8.64M | 0.05% |
308,545
+41,753
| +16% | +$1.22M |
|
|
FOLD
261
DELISTED
Amicus Therapeutics
FOLD
| $8.61M | 0.05% |
708,239
+59,727
| +9% | +$770K |
|
262
CRISPR Therapeutics
CRSP
$4.73B
| $8.6M | 0.05% |
189,387
+42,478
| +29% | +$2.19M |
|
263
American Tower
AMT
$80.8B
| $8.56M | 0.05% |
52,082
+2,546
| +5% | +$465K |
|
264
General Dynamics
GD
$104B
| $8.51M | 0.05% |
38,525
+871
| +2% | +$193K |
|
265
Kinder Morgan
KMI
$71.7B
| $8.5M | 0.05% |
512,594
-83,308
| -14% | -$1.44M |
|
|
SAGE
266
DELISTED
Sage Therapeutics
SAGE
| $8.48M | 0.05% |
411,904
+273,257
| +197% | +$7.89M |
|
267
Recursion Pharmaceuticals
RXRX
$1.59B
| $8.45M | 0.05% |
1,104,526
+784,113
| +245% | +$7.82M |
|
268
GlobalFoundries
GFS
$27.4B
| $8.45M | 0.05% |
145,162
+30,855
| +27% | +$1.83M |
|
269
Ironwood Pharmaceuticals
IRWD
$696M
| $8.42M | 0.05% |
874,052
+148,881
| +21% | +$1.46M |
|
|
BPMC
270
DELISTED
Blueprint Medicines
BPMC
| $8.37M | 0.05% |
166,690
+24,693
| +17% | +$1.32M |
|
271
AstraZeneca
AZN
$263B
| $8.36M | 0.05% |
61,748
+14,292
| +30% | +$1.95M |
|
272
Vaxcyte
PCVX
$7.81B
| $8.36M | 0.05% |
163,894
-415
| -0.3% | -$20.5K |
|
273
T. Rowe Price
TROW
$23.9B
| $8.35M | 0.05% |
79,580
+3,922
| +5% | +$442K |
|
274
lululemon athletica
LULU
$13.5B
| $8.34M | 0.05% |
21,622
+2,978
| +16% | +$1.14M |
|
275
Krystal Biotech
KRYS
$10.1B
| $8.33M | 0.05% |
71,806
+18,623
| +35% | +$2.27M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Rafferty Asset Management held 1,117 positions worth $17B, down 4.1% from $17.7B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Rafferty Asset Management's Q3 2023 filing shows 28 new, 595 increased, 447 reduced and 45 closed positions. Its largest new stake was Rambus: 596,990 shares worth $33.3M. The largest sale was NVIDIA, an estimated $109M.
By sector, the portfolio is most concentrated in Technology at 43% of assets, down from 46% a quarter earlier, followed by Financials and Healthcare.
- Rafferty Asset Management's largest Q3 2023 buy was Rambus: 596,990 shares worth $33.3M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q3 2023, an estimated $226M increase.
- Rafferty Asset Management's biggest Q3 2023 reduction was NVIDIA, cutting an estimated $109M.
- Rafferty Asset Management fully exited Silicon Laboratories in Q3 2023, selling an estimated $28.9M.
- Rafferty Asset Management's ten largest holdings make up 35% of its $17B portfolio in Q3 2023.
- Rafferty Asset Management opened 28 new positions and closed 45 in Q3 2023.
- Rafferty Asset Management's portfolio value fell 4.1% quarter-over-quarter to $17B.
Based on Rafferty Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.